Breast Cancer De-Escalation: Defining When Less Treatment Is Enough

The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.

By
October 13, 2026
9 min

Baptist Health South Florida

1

Breast cancer de-escalation uses tumor biology and treatment response to tailor therapy, aiming to avoid excess toxicity while preserving oncologic goals.
2

For selected patients with early-stage hormone receptor-positive, HER2-negative disease, genomic assays can help identify those who may safely omit adjuvant chemotherapy.
3

The ongoing SWOG S2212 (SCARLET) trial is evaluating a shorter, anthracycline-free chemo-immunotherapy regimen for early-stage triple-negative breast cancer.
4

Pathologic complete response after neoadjuvant therapy is associated with favorable long-term outcomes and may inform less intensive subsequent treatment in selected settings.
5

Neoadjuvant therapy, imaging, and biopsy can support less extensive breast and axillary surgery for appropriate patients, potentially reducing surgical morbidity.

Breast Cancer De-Escalation: Defining When Less Treatment Is Enough

1

2

3

4

5

Original Source(s)

Breast Cancer De-Escalation: Defining When Less Treatment Is Enough

Related Content

Medically Assisted Reproduction and Hormone-Related Cancers

2026 ASCO Breast Cancer Highlights: Food Access, Poverty, and MBC

Error in the Byline